AbbVie's stock and next megablockbuster take hits following new JAK warnings from FDA

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 1, 2021 at 11:22 PM.

  1. #1 cafead, Sep 1, 2021 at 11:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via While the FDA’s new warnings on JAK inhibitors are based on a review of a Pfizer trial, it’s AbbVie that may be hurt the most.

    AbbVie’s stock fell by about 10% at one point Wednesday as its prized JAK inhibitor Rinvoq, once forecast to haul in $8 billion annually by 2025, was looped into new class-wide FDA warnings, which include risks of serious heart-related events, cancer, blood clots and death.

    article source
     
    Quote

Reply to Thread